The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282 ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and ...

Privately-held Alchemab Therapeutics, a biotech that uses the power of human immune evolution to identify and develop ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for ...